Biotech Investing
The Longevity Dividend: Why Investing in Anti-Ageing Science is the Next Frontier in Finance
Longevity science is evolving into a multi-trillion-dollar industry, creating a paradigm shift for finance, investing, and the global economy.
The Trillion-Dollar Bug: How AI and New Financial Models Are Fuelling the War on Superbugs
A new GSK-backed venture uses AI and innovative financial models to combat the growing economic and health threat of drug-resistant superbugs.
Merck’s Strategic Gambit: Why a Potential Deal for Cidara’s Flu Drug Could Reshape Preventative Medicine and Your Portfolio
Merck’s potential acquisition of Cidara Therapeutics signals a major shift in flu prevention, impacting healthcare, finance, and the broader economy.
The $600M Bet: How the Global Race for Weight-Loss Drugs is Rewriting the Rules of Biotech Investing and Tapping into China’s R&D Power
A US biotech’s $600M raise for weight-loss drugs reveals a key strategy: using China for faster, cheaper clinical trials, altering biotech investing.